Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 1, 137-138 doi:10.3324/haematol.10489
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Illmer, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Illmer, T.

Acute Myeloid Leukemia

Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias

Thomas Illmer, Markus Schaich, Gerhard Ehninger, Christian Thiede on behalf of the DSIL2003 AML study group

Medical Clinic and Policlinic I, University Hospital of the Technical University Dresden, Germany

Correspondence: Thomas Illmer, Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität, Fetscherstrasse 74, 01307 Dresden, Germany. Phone: international +49.351.4584695. Fax: international +49.351.4585362. E-mail: thomas.illmer{at}uniklinikum-dresden.de

We investigated a large number of acute myeloid leukemia (AML) samples (n=959) for the presence of the JAK2 V617F mutation. We found a low incidence of the mutation in these AML samples (1%). JAK2 V617F mutations clustered in AML samples with an aberrant karyotype (p<0.05). The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01). Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.

Key words: JAK2, AML, CBF-leukemias.




This article has been cited by other articles:


Home page
 haematolHome page
E. Iwanaga, T. Nanri, N. Matsuno, T. Kawakita, H. Mitsuya, and N. Asou
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia
Haematologica, March 1, 2009; 94(3): 433 - 435.
[Full Text] [PDF]

Home page
 haematolHome page
T. Akagi, S. Ogawa, M. Dugas, N. Kawamata, G. Yamamoto, Y. Nannya, M. Sanada, C. W. Miller, A. Yung, S. Schnittger, et al.
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype
Haematologica, February 1, 2009; 94(2): 213 - 223.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. P. Maciejewski and G. J. Mufti
Whole genome scanning as a cytogenetic tool in hematologic malignancies
Blood, August 15, 2008; 112(4): 965 - 974.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. W. Tyner, D. K. Walters, S. G. Willis, M. Luttropp, J. Oost, M. Loriaux, H. Erickson, A. S. Corbin, T. O'Hare, M. C. Heinrich, et al.
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
Blood, February 15, 2008; 111(4): 2238 - 2245.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.